NEW YORK (GenomeWeb News) – Agilent Technologies today named the Massachusetts Eye and Ear Infirmary as a certified service provider of the company's next-generation sequencing target enrichment and microarray-based comparative genomic hybridization solutions.
MEEI is an affiliate of Harvard Medical School and home to the school's Department of Opthalmology Ocular Genomics Institute. Using genomics and gene therapy, the institute is working to advance knowledge and treatment of blinding eye diseases, Agilent said.
As a member of Agilent's CSP program, MEEI will have access to the firm's latest protocols and technologies. "It is our hope that these tools will help advance studies in genomic research and gene therapy," Ocular Genomics Institute Director Eric Pierce said in a statement.
"In addition, incorporating the Agilent Bravo Automated Liquid Handling platform into our service offerings will enable us to quickly process large volumes of samples for even more researchers and for a wide range of genomics applications. We are using these approaches to provide improved clinical genetic diagnostic testing services for patients with inherited eye disorders," he added.